DALLAS, NEW YORK, LONDON, and TOKYO – In a significant move reshaping the pharmaceutical and nutraceutical ingredient landscape, Lone Star Funds has reached a definitive agreement to acquire the Capsules & Health Ingredients (CHI) division of Lonza Group AG. The deal, announced on March 6, 2026, values the business at an enterprise value of CHF 2.3 billion (approximately USD 3 billion at closing), according to a press release from Lonza. This acquisition signals a strategic shift for both companies, with Lonza focusing on its core contract development and manufacturing organization (CDMO) business and Lone Star expanding its portfolio in the health and wellness sector.
The transaction, expected to close in the second half of 2026, will see Lone Star acquire a leading global manufacturer of capsules and health ingredients. Notably, Lonza will retain a 40% equity position in the business, demonstrating continued confidence in CHI’s future prospects. This isn’t simply a divestment; it’s a restructuring designed to unlock value and allow each entity to concentrate on its respective strengths. The move comes as Lonza aims to complete its transformation into a pure-play CDMO, a strategy it has been signaling for some time, and allows it to reinvest capital into higher-growth areas.
CHI operates globally, with a strong presence across the Americas, Europe, and the Asia Pacific region. The division is comprised of three key segments: Hard Empty Capsules, a leading producer of gelatin and plant-based capsules; Dosage Form Solutions, offering end-to-end development and manufacturing services; and Health Ingredients, providing branded, science-backed nutritional ingredients. These segments serve a diverse customer base in both the pharmaceutical and nutraceutical industries, capitalizing on growing demand for innovative and high-quality health solutions. The acquisition by Lone Star is expected to provide CHI with the resources and flexibility to accelerate growth and innovation within these markets.
Lone Star’s Vision for CHI: Independence and Growth
Lone Star Funds, a private equity firm with approximately $95 billion in committed capital across 25 funds as of March 6, 2026, believes CHI possesses significant potential as a standalone business. Donald Quintin, Chief Executive Officer of Lone Star, stated that the company sees a “significant opportunity” for CHI to enhance operational focus, invest in innovation, and pursue strategic growth initiatives. This suggests a plan to empower CHI’s management team and provide the necessary capital to capitalize on emerging trends in the health and wellness market. The firm’s track record of investing in and growing businesses suggests a long-term commitment to CHI’s success.
The appeal of CHI lies in its strong technical capabilities, differentiated product offerings, and established customer relationships. As an independent operator, the company will be better positioned to respond quickly to market changes and tailor solutions to meet the evolving needs of its customers. This agility is particularly important in the rapidly growing nutraceuticals sector, where consumer demand for personalized and science-backed health products is increasing. The company benefits from operating in markets characterized by strong underlying demand growth, providing a solid foundation for future expansion.
Lonza’s Strategic Shift: Focusing on CDMO
For Lonza Group AG, the sale of CHI represents a pivotal step in its transformation into a focused CDMO. The company plans to invest the upfront proceeds of CHF 1.7 billion (approximately USD 2.2 billion) into organic growth opportunities and bolt-on acquisitions aligned with its One Lonza Strategy. This strategic move allows Lonza to concentrate its resources and expertise on its core competencies in contract development and manufacturing, a sector experiencing robust growth driven by increasing demand for outsourced pharmaceutical manufacturing services.
Lonza anticipates total proceeds, including upfront payments and future exit proceeds, to reach at or above CHF 3 billion (approximately USD 4 billion). The retention of a 40% stake in CHI provides Lonza with continued exposure to the upside potential of the business while allowing it to streamline its operations and focus on its CDMO objectives. This arrangement allows Lonza to benefit from CHI’s future success without the operational complexities of managing a diverse portfolio of businesses. The company’s decision reflects a broader trend in the pharmaceutical industry towards specialization and outsourcing.
Understanding the CDMO Model
The Contract Development and Manufacturing Organization (CDMO) model has become increasingly prevalent in the pharmaceutical industry. CDMOs provide a range of services, from drug development and formulation to manufacturing and packaging, allowing pharmaceutical companies to outsource these functions and focus on their core competencies, such as research and marketing. This model offers several advantages, including reduced costs, increased flexibility, and access to specialized expertise. Lonza’s commitment to becoming a pure-play CDMO positions it to capitalize on the growing demand for these services.
Impact on the Pharmaceutical and Nutraceutical Industries
The acquisition of CHI by Lone Star Funds is expected to have a ripple effect throughout the pharmaceutical and nutraceutical industries. The increased independence of CHI could lead to greater innovation and responsiveness to customer needs. Lone Star’s investment is likely to fuel research and development efforts, resulting in new and improved capsule technologies and health ingredients. This, in turn, could benefit consumers by providing access to more effective and innovative health products.
The deal also highlights the growing interest of private equity firms in the health and wellness sector. Driven by aging populations, increasing health awareness, and rising disposable incomes, the demand for health products and services is expected to continue to grow in the coming years. This makes companies like CHI attractive targets for investors seeking to capitalize on these trends. The transaction could potentially spur further consolidation in the industry as other private equity firms glance to acquire similar businesses.
Key Takeaways
- Lone Star Funds is acquiring the Capsules & Health Ingredients (CHI) division of Lonza Group AG for CHF 2.3 billion.
- Lonza will retain a 40% equity stake in CHI and will focus on its core CDMO business.
- The acquisition is expected to close in the second half of 2026, subject to regulatory approvals.
- Lone Star plans to invest in CHI to enhance its operational focus and accelerate growth.
- The deal reflects a broader trend towards specialization and outsourcing in the pharmaceutical industry.
The completion of this transaction is subject to customary closing conditions and regulatory approvals. Industry analysts will be closely watching how Lone Star integrates CHI and executes its growth strategy. Further updates on the deal’s progress and Lonza’s transformation will likely be released in the coming months. The next key milestone will be the official closing of the acquisition, anticipated before the end of 2026.
What are your thoughts on this significant industry shift? Share your insights and perspectives in the comments below. Don’t forget to share this article with your network to keep the conversation going.
Worth a look